arrow
G

Grace Kong

peter maccallum cancer center
H指数:39
被引数:6,649

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis

转移性去势抵抗性前列腺癌患者中初始影像和PSA变化对[177Lu]Lu-PSMA-617放射性药物治疗的预后价值:一项ProsTIC登记研究分析

2025-12-011
PRE
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network
2025-11-010
PRE
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

镥-177 [177Lu]Lu-PSMA-I&T 联合镭-223 治疗转移性去势抵抗性前列腺癌(AlphaBet 研究):一项研究者发起、单中心、单臂、Ⅰ/Ⅱ期试验的期中分析

2025-10-180
PRE
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

钽-161 [161Tb]Tb-PSMA-I&T双β–Auger放射性配体疗法在转移性去势抵抗性前列腺癌患者中的首次人体研究结果(VIOLET):一项单中心、单臂、I/II期研究

2025-07-030
PRE
Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience

[177Lu]Lu-DOTA-奥曲肽放射性核素疗法在进展性胃肠胰神经内分泌肿瘤中重复治疗的 safety 和 efficacy:一项单中心经验

2025-03-260
OA
Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer

LuCAB临床试验方案:一项评估卡巴他赛联合[177Lu]Lu-PSMA-617治疗转移性去势抵抗性前列腺癌的I-II期临床试验

2025-02-200
PRE
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series

[177Lu]Lu-PSMA治疗后转移性去势抵抗性前列腺癌患者中的治疗相关髓系肿瘤:一个病例系列

2025-02-201
PRE
Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

循环肿瘤细胞 (ctc) 的分子特征与对177Lu-PSMA-617加pembrolizumab治疗转移性去势抵抗性前列腺癌 (mCRPC) 的反应相关

2023-10-010
PRE
Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT)
2022-09-013
OA